Global Allergic Rhinitis Drugs Market 2016-2020

  • ID: 3619099
  • Report
  • Region: Global
  • 90 pages
  • TechNavio
1 of 5

FEATURED COMPANIES

  • Adamis Pharmaceuticals
  • Apotex
  • Circassia Pharmaceuticals
  • Hanmi Pharmaceuticals
  • Mylan
  • Revance Therapeutics
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

About Allergic Rhinitis Drugs

Allergic rhinitis is caused by the interaction of airborne allergens with specific immunoglobulin E (IgE) type antibodies on the surface of mast cells. This interaction causes mast cells to release and synthesize chemicals, causing inflammation of the surrounding tissues. Typical symptoms include rhinorrhea, nasal itching, sneezing, and nasal congestion. Extranasal symptoms such as allergic conjunctivitis, itchy ears and palate, and asthma may also occur. Allergic rhinitis is treated using medications such as antihistamines, intranasal corticosteroids, or immunotherapies. Alternative forms of treatment are also employed in certain cases.

The analysts forecast the global allergic rhinitis market to grow at a CAGR of 0.95% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global allergic rhinitis drugs market for the period 2016-2020. To calculate the market size, it considers revenue generated from the sales of prescription and off-label drugs used to treat allergic rhinitis.

The market is divided into the following segments based on geography:
- Americas
- APAC
- Europe

The report, Global Allergic Rhinitis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- AstraZeneca
- GlaxoSmithKline
- Meda Pharmaceuticals
- Merck
- Sanofi
- UCB

Other prominent vendors
- Adamis Pharmaceuticals
- Alcon
- Alergo Pharma
- ALK-Abelló
- Allergy Therapeutics
- Almirall
- Ampio
- Anergis
- Apotex
- Ares Life Sciences
- Array BioPharma
- Aspen Pharmacare
- Atopix Therapeutics
- Barr Laboratories
- Belcher Pharmaceuticals
- Circassia Pharmaceuticals
- Dainippon Sumitomo
- DBV Technologies
- Dr Reddy's Laboratories
- Eddingpharm
- Genentech
- Greer Laboratories
- Hanmi Pharmaceuticals
- Hisamitsu Pharmaceutical
- Intas Pharmaceuticals
- Kyowa Hakko
- Lupin Pharmaceuticals
- Mitsubishi Tanabe Pharma
- Mylan
- Nektar Therapeutics
- Novartis
- Nuvo Research
- Nycomed
- Omega Pharma
- Ono Pharmaceuticals
- Pfizer
- Revance Therapeutics
- Roxane Laboratories (Boehringer Ingelheim)
- Shionogi
- Stallergenes
- Sun Pharmaceuticals
- Takeda Pharmaceutical
- Teva Pharmaceuticals
- Verona Pharma
- VentiRx Pharmaceuticals

Market drivers
- Increased prevalence of allergic rhinitis
- For a full, detailed list, view the full report

Market challenges
- Patent expiries and competition from generic drugs
- For a full, detailed list, view the full report

Market trends
- Increased R&D
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Adamis Pharmaceuticals
  • Apotex
  • Circassia Pharmaceuticals
  • Hanmi Pharmaceuticals
  • Mylan
  • Revance Therapeutics
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

PART 01: Executive summary
  • Highlights
PART 02: Scope of the report
  • Market overview
  • Top-vendor offerings
PART 03: Market research methodology
  • Research methodology
  • Economic indicators
PART 04: Introduction
  • Key market highlights
PART 05: Overview: Allergic rhinitis
  • Understanding the disease
  • Classification of allergic rhinitis
  • Causes
  • Signs and symptoms
  • Risk factors
  • Diagnosis and testing
  • Treatment
  • Epidemiology
  • Economic burden and impact on quality of life
PART 06: Pipeline analysis
  • Information on pipeline candidates
  • Clinical trial information of allergic rhinitis
PART 07: Market landscape
  • Market overview
  • Market size and forecast
  • Five forces analysis
PART 08: Market segmentation based on class of drugs
  • Antihistamines
  • Intranasal corticosteroids
  • Immunotherapies
  • Global antihistamines drugs market
  • Global intranasal corticosteroids drugs market
  • Global immunotherapies drugs market
PART 09: Market segmentation by route of administration
  • Oral
  • Parenteral
  • Intranasal
PART 10: Market segmentation by dosage form
  • Solid
  • Liquid
PART 11: Geographical segmentation
  • Global allergic rhinitis drugs market by geography 2015-2020
  • Allergic rhinitis drugs market in Americas
  • Allergic rhinitis drugs market in EMEA
  • Allergic rhinitis drugs market in APAC
PART 12: Market drivers
  • Increased prevalence of allergic rhinitis
  • Rise in awareness about allergic rhinitis
  • High usage of tobacco
  • Presence of high unmet medical needs
PART 13: Impact of drivers

PART 14: Market challenges
  • Increased preference for CAM
  • Patent expiries and competition from generic drugs
  • Adverse effects of drugs
  • Poor patient adherence
PART 15: Impact of drivers and challenges

PART 16: Market trends
  • Self-medication using OTC products
  • Increased R&D
  • Intense competition
  • Strategic alliances
PART 17: Vendor landscape
  • Competitive scenario
  • Market share analysis 2015
  • AstraZeneca
  • GlaxoSmithKline
  • Meda Pharmaceuticals
  • Merck
  • Sanofi
  • UCB
  • Other prominent vendors
PART 18: Appendix
  • List of abbreviations
PART 19: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Types of allergic rhinitis
Exhibit 03: Risk factors associated with allergic rhinitis
Exhibit 04: Major diagnostic procedures for allergic rhinitis
Exhibit 05: Imaging studies used to diagnose and evaluate allergic rhinitis
Exhibit 06: Summary of pharmacologic treatments for allergic rhinitis
Exhibit 07: Non-pharmacological therapies for allergic rhinitis
Exhibit 08: Examples of non-pharmacological therapies
Exhibit 09: Treatment algorithm of allergic rhinitis
Exhibit 10: Prevalence of allergic rhinitis in China
Exhibit 11: Global allergic rhinitis drugs market: Pipeline portfolio
Exhibit 12: Allergic rhinitis clinical trials by development phase 2015
Exhibit 13: Allergic rhinitis clinical trials by trial status 2015
Exhibit 14: Global allergic rhinitis drugs market 2015-2020 ($ billions)
Exhibit 15: Five forces analysis
Exhibit 16: Global allergic rhinitis market based on class of drugs
Exhibit 17: Examples of prescription and OTC intranasal corticosteroids
Exhibit 18: Global allergic rhinitis drugs market based on class of drugs 2015
Exhibit 19: Global allergic rhinitis drugs market based on class of drugs 2015-2020 ($ billions)
Exhibit 20: Global antihistamines drugs market 2015-2020 ($ billions)
Exhibit 21: Global intranasal corticosteroids drugs market 2015-2020 ($ billions)
Exhibit 22: Global immunotherapies drugs market 2015-2020 ($ billions)
Exhibit 23: Global allergic rhinitis drugs market by route of administration
Exhibit 24: Global allergic rhinitis drugs market segmentation by dosage form
Exhibit 25: Global allergic rhinitis drugs market by geography 2015
Exhibit 26: Global allergic rhinitis drugs market revenue by geography 2015-2020 ($ billions)
Exhibit 27: Allergic rhinitis drugs market in Americas 2015-2020 ($ billions)
Exhibit 28: Allergic rhinitis drugs market in EMEA 2015-2020 ($ billions)
Exhibit 29: Allergic rhinitis drugs market in APAC 2015-2020 ($ millions)
Exhibit 30: Drivers of global allergic rhinitis drugs market
Exhibit 31: Impact of drivers
Exhibit 32: Challenges of global allergic rhinitis drugs market
Exhibit 33: Impact of drivers and challenges
Exhibit 34: Trends of global allergic rhinitis drugs market
Exhibit 35: Drugs that underwent Rx-to-OTC switch in the US
Exhibit 36: Global allergic rhinitis drugs market vendor share analysis 2015
Exhibit 37: YoY revenue comparison of top drugs for allergic rhinitis 2012-2014 ($ billions)
Exhibit 38: AstraZeneca: Business segmentation by revenue 2014
Exhibit 39: AstraZeneca: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 40: AstraZeneca: Geographical segmentation by revenue 2014
Exhibit 41: AstraZeneca: Key takeaways
Exhibit 42: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 43: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 44: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 45: GlaxoSmithKline: YoY growth and revenue of Avamys/Veramyst 2012-2014 ($ millions)
Exhibit 46: GlaxoSmithKline: Key takeaways
Exhibit 47: Meda Pharmaceuticals: Product segmentation by revenue 2014
Exhibit 48: Meda Pharmaceuticals: Product segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 49: Meda Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 50: Meda Pharmaceuticals: Top-selling drugs
Exhibit 51: Meda Pharmaceuticals: YoY growth and revenue of Dymista 2012-2014 ($ millions)
Exhibit 52: Meda Pharmaceuticals: YoY growth and revenue of EpiPen 2012-2014 ($ millions)
Exhibit 53: Meda Pharmaceuticals: Key takeaways
Exhibit 54: Merck: Business segmentation by revenue 2014
Exhibit 55: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 56: Merck: Geographical segmentation by revenue 2014
Exhibit 57: Merck: Top-selling drugs
Exhibit 58: Merck: YoY growth and revenue of Nasonex 2012-2014 ($ billions)
Exhibit 59: Merck: YoY growth and revenue of Singulair 2012-2014 ($ billions)
Exhibit 60: Merck: YoY growth and revenue of Clarinex 2012-2014 ($ millions)
Exhibit 61: Merck: Key takeaways
Exhibit 62: Sanofi: Business segmentation by revenue 2014
Exhibit 63: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 64: Sanofi: Geographical segmentation by revenue 2014
Exhibit 65: Sanofi: Top-selling drugs
Exhibit 66: Sanofi: YoY growth and revenue of Allegra 2012-2014 ($ millions)
Exhibit 67: Sanofi: YoY growth and revenue of Allegra OTC 2012-2014 ($ millions)
Exhibit 68: Sanofi: YoY revenue comparison of Nasacort ($ millions)
Exhibit 69: Sanofi: Key takeaways
Exhibit 70: UCB: Product segmentation by revenue 2014
Exhibit 71: UCB: Product segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 72: UCB: Geographical segmentation by revenue 2014
Exhibit 73: UCB: YoY growth and revenue of Zyrtec 2012-2014 ($ millions)
Exhibit 74: UCB: YoY growth and revenue of Xyzal 2012-2014 ($ millions)
Exhibit 75: UCB: Key takeaways
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Adamis Pharmaceuticals
  • Apotex
  • Circassia Pharmaceuticals
  • Hanmi Pharmaceuticals
  • Mylan
  • Revance Therapeutics
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

New Report Released: – Global Allergic Rhinitis Drugs Market 2016-2020

The author of the report recognizes the following companies as the key players in the Global Allergic Rhinitis Drugs Market: AstraZeneca, GlaxoSmithKline, Meda Pharmaceuticals, Merck, Sanofi and UCB.

Other Prominent Vendors in the market are: Adamis Pharmaceuticals, Alcon, Alergo Pharma, ALK-Abello, Allergy Therapeutics, Almirall, Ampio, Anergis, Apotex, Ares Life Sciences, Array BioPharma, Aspen Pharmacare, Atopix Therapeutics, Barr Laboratories, Belcher Pharmaceuticals, Circassia Pharmaceuticals, Dainippon Sumitomo, DBV Technologies, Dr Reddy's Laboratories, Eddingpharm, Genentech, Greer Laboratories, Hanmi Pharmaceuticals, Hisamitsu Pharmaceutical, Intas Pharmaceuticals, Kyowa Hakko, Lupin Pharmaceuticals, Mitsubishi Tanabe Pharma, Mylan, Nektar Therapeutics, Novartis, Nuvo Research, Nycomed, Omega Pharma, Ono Pharmaceuticals, Pfizer, Revance Therapeutics, Roxane Laboratories (Boehringer Ingelheim), Shionogi, Stallergenes, Sun Pharmaceuticals, Takeda, Teva Pharmaceuticals, Verona Pharma, and VentiRx Pharmaceuticals.

Commenting on the report, an analyst from the research team said: “The growing incidence of allergic rhinitis is leading to the demand for advanced and efficient medications. Also, vendors are striving to cater to the unmet medical needs in the market. Drugs such as S-524101, S-555739, and STAGR 320 are in the Phase III stage of development. The launch of these drugs, which have an improved safety and efficacy profile, will drive the growth of the global allergic rhinitis drugs market during the forecast period.”

According to the report, the rising prevalence of allergic rhinitis worldwide to play a major role in the growth of the market during the forecast period. Exposure to pollutants in the atmosphere such as vehicular emissions, pollen, or animal dander is a major cause for the rise in the incidence of allergic rhinitis. A decline in the air quality of major cities worldwide is also expect to lead to a rise in the number of people with the condition. An increase in tobacco usage also propels market growth.

Further, the report states that patent expiries of major drugs is however, expected to hinder the growth of the market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

- AstraZeneca
- GlaxoSmithKline
- Meda Pharmaceuticals
- Merck
- Sanofi
- UCB
- Adamis Pharmaceuticals
- Alcon
- Alergo Pharma
- ALK-Abello
- Allergy Therapeutics
- Almirall
- Ampio
- Anergis
- Apotex
- Ares Life Sciences
- Array BioPharma
- Aspen Pharmacare
- Atopix Therapeutics
- Barr Laboratories
- Belcher Pharmaceuticals
- Circassia Pharmaceuticals
- Dainippon Sumitomo
- DBV Technologies
- Dr Reddy's Laboratories
- Eddingpharm
- Genentech
- Greer Laboratories
- Hanmi Pharmaceuticals
- Hisamitsu Pharmaceutical
- Intas Pharmaceuticals
- Kyowa Hakko
- Lupin Pharmaceuticals
- Mitsubishi Tanabe Pharma
- Mylan
- Nektar Therapeutics
- Novartis
- Nuvo Research
- Nycomed
- Omega Pharma
- Ono Pharmaceuticals
- Pfizer
- Revance Therapeutics
- Roxane Laboratories (Boehringer Ingelheim)
- Shionogi
- Stallergenes
- Sun Pharmaceuticals
- Takeda
- Teva Pharmaceuticals
- Verona Pharma
- VentiRx Pharmaceuticals.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll